











York,	 felt	 almost	 post-apocalyptic:	 subways	 were	 empty,	 traffic	 had	
thinned,	and	the	piercing	wail	of	ambulance	sirens	echoed	through	the	
otherwise	empty	streets.		Less	than	two	months	after	the	first	confirmed	
COVID-19	 case	 in	 the	 United	 States,	 the	 World	 Health	 Organization	
(WHO)	declared	COVID-19	a	pandemic	on	March	11,	2020.1		COVID-19,	
the	disease	caused	by	the	novel	coronavirus	SARS-CoV-2,	brought	the	




preexisting	 conditions	 and	 geographic	 location,	were	 associated	with	
greater	infection	and	death	rates.3		Data	also	shows	that	race	or	ethnicity	
plays	 a	 role	 in	 susceptibility	 to	 COVID-19	 and	 that	 racial	 and	 ethnic	
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review	 of	 COVID-19	 cases	 in	 England	 found	 that	 Black	 and	 Asian	
individuals	 are	 at	 a	 higher	 risk	 of	 COVID-19	 mortality	 even	 when	
controlling	for	factors	such	as	age	and	comorbidity.5		This	is	consistent	
with	general	knowledge	of	racial	health	disparities	in	the	United	States.6		
In	 addition	 to	 the	 COVID-19	 pandemic,	 2020	 saw	 widespread	
support	for	the	Black	Lives	Matter	movement,	sparked	by	outrage	over	
the	 public	 murder	 of	 George	 Floyd	 by	 Minneapolis	 police	 officers.7		
Worldwide	protests	have	called	for	an	end	to	systemic	racism,	and	the	











Phase	 III	 clinical	 trials	 receiving	NIH	 funding,	 the	U.S.	Food	and	Drug	
Administration	 (FDA),	 which	 oversees	 clinical	 trials	 of	 drugs	 and	
medical	devices,	has	merely	issued	non-binding	guidance	encouraging	
diversity	in	clinical	trial	participants.10		These	efforts	have	been	largely	
unsuccessful.11	 	 This	 Comment	 will	 argue	 that	 to	 reduce	 racial	
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Vaccine	 Trials,	 N.Y.	TIMES	 (Sept.	 11,	 2020),	 https://www.nytimes.com/2020/09/11/
opinion/vaccine-testing-black-americans.html	 (“[T]he	 largest	 population	 being	 killed	
by	Covid-19	should	have	a	significant	role	in	development	of	a	treatment.”).		Moderna	










regulations	requiring	drug	developers	 to	 increase	diversity	of	 clinical	
trial	 participants,	 especially	 when	 the	 disease	 that	 the	 drug	 or	
intervention	targets	disproportionately	affects	minority	populations.		
Part	II	of	this	Comment	will	briefly	review	the	history	of	healthcare	
disparities	 in	 minority	 populations	 and	 the	 medical	 and	 social	
significance	of	these	disparities.		This	Part	will	also	examine	how	racial	
disparities	have	played	out	 in	 the	context	of	 the	COVID-19	pandemic.		
Part	 III	 will	 provide	 a	 brief	 overview	 of	 the	 FDA’s	 role	 in	 regulating	
clinical	trials	to	provide	context	for	why	the	FDA	is	the	correct	entity	to	














Healthcare	 disparities	 are	 systemic	 and	 consistent	 differences,	
such	 as	 greater	 health	 risks	 and	 worse	 health	 outcomes,	 in	
disadvantaged	social	groups	such	as	racial	and	ethnic	minorities.12		For	
example,	mortality	rates	from	heart	disease,	stroke,	and	certain	cancers	
are	 much	 higher	 in	 Black	 populations;	 diabetes	 rates	 in	 Native	
Americans	and	Latinx	are	30	percent	higher	than	White	Americans;	and	
Black	 Americans’	 life	 expectancy	 is	 nearly	 ten	 years	 less	 than	White	
 
ethnic	diversity	compared	to	last	year’s	approved	drugs’	clinical	trials,	which	included	
69%	 White	 participants,	 11%	 Black	 or	 African	 American,	 10%	 Asian	 and	 14%		
Hispanic.”);	Hala	T.	Borno	et	al.,	COVID-19	Disparities:	An	Urgent	Call	for	Race	Reporting	
and	 Representation	 in	 Clinical	 Research,	 CONTEMP.	 CLINICAL	 TRIALS	 COMMC’NS	 (July	 30,	
2020),	 https://www.sciencedirect.com/science/article/pii/S2451865420301149	 (“In	
the	United	States,	racial/ethnic	minorities	remain	underrepresented	in	clinical	research	







minority	 communities	 from	having	 equal	 or	 even	 adequate	 access	 to	
health	care,	including	economic	factors;	linguistic,	cultural,	or	religious	
barriers;	and	geographic	barriers.14			









impact	 the	 care	 they	provide	 to	minority	patients.	 	 Still,	 experiments	
have	 shown	 that	 physicians	 whose	 Implicit	 Association	 Test	 (IAT)	
results	 showed	 anti-Black	 bias	 were	 less	 likely	 to	 prescribe	 pain	
medications	 and	 specific	 (effective)	 treatments	 for	 heart	 disease	 to	
Black	 patients	 compared	 to	 White	 patients.18	 	 In	 conjunction	 with	
structural	 factors,	 healthcare	 providers’	 implicit	 biases	 dramatically	
compromise	 the	 quality	 of	 care	 and	 health	 outcomes	 for	 racial	 and	
ethnic	minorities.		
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of	 the	most	well-known	examples	of	 this	exploitation	 is	 the	Tuskegee	
Syphilis	 Study,	 where	 Black	 men	 with	 syphilis	 were	 “enrolled”	 in	 a	
clinical	study	without	their	knowledge	or	consent.20		Because	the	study’s	
purpose	was	to	track	the	natural	progression	of	untreated	syphilis,	the	
men	 did	 not	 receive	 treatment	 for	 the	 disease	 even	 when	 penicillin	
became	 a	 widely	 accepted	 cure.21	 	 To	 this	 day,	 historical	 distrust	 is	
reinforced	by	 the	 fact	 that	Black	patients	 tend	 to	have	worse	 clinical	
outcomes	than	White	patients.22			











trust	 in	 the	 medical	 system	 may	 reduce	 healthcare	 disparities	 and	






Americans	 to	 this	 day.	 	 For	 a	 detailed	 history,	 see	 generally	 HARRIET	A.	WASHINGTON,	
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Why,	 HILL	 (Aug.	 24,	 2017),	 https://thehill.com/blogs/pundits-blog/healthcare/
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above,	 the	 participant	 recruitment	 and	 referral	 processes	 inhibit	
minority	access	to	clinical	trials.28		A	paper	from	the	Endocrine	Society	
noted	that,		
[P]harmaceutical	 companies	 and	 CROs	 [(Contract	 Research	
Organizations)]	only	recruit	physicians	with	a	track	record	of	
clinical	 research.	 	 Therefore,	 physicians	with	 an	 interest	 in	
clinical	 research,	 but	 with	 little	 experience,	 lack	 the	
opportunities	 to	 participate	 in	 enough	 clinical	 trials	 to	
maintain	the	infrastructure	that	they	have	worked	so	hard	to	
build.	 	 This	 results	 in	 minority	 physicians	 being	 under-




research	 even	when	 a	 particular	 disease	 disproportionately	 affects	 a	
minority	 group	 or	 groups.	 	 For	 example,	 one	 in	 five	 Americans	




Clinical	 trials	must	 include	members	 of	minority	 populations	 to	
ensure	that	the	results	of	those	trials	are	relevant	to	those	populations.		
Many	 diseases	 disproportionately	 affect	 minority	 populations,31	 and	
clinical	trials	should	include	members	of	such	populations	to	ensure	the	
interventions	 developed	 will	 benefit	 the	 populations	 who	 are	 most	
affected	 by	 the	 disease.32	 	 One	 of	 the	most	 common	 justifications	 for	
including	minority	populations	in	clinical	trials	is	genetics.		Genetics	can	
 






















Because	 racial	 categories	 are	 social	 constructs	 rather	 than	
biological	 facts,	 membership	 in	 a	 self-defined	 racial	 group	 does	 not	
define	one’s	genetic	makeup.		In	fact,	looking	at	genetics	alone,	scientists	
cannot	distinguish	between	races.36		Even	when	certain	genetic	features	
can	be	grouped	and	associated	with	 “quasi-distinct”	 categories,	 these	
categories	do	not	align	with	 socially-constructed	 racial	 groups.37	 	 For	
example,	 there	 could	 be	more	 genetic	 similarities	 between	 a	 racially	
Asian	 individual	 and	 a	 racially	 White	 individual	 than	 between	 two	
racially	Black	individuals.38		And	while	certain	genes	can	impact	rates	of	
disease	 and	 pharmaceutical	 metabolism,	 these	 genes	 “do	 not	 align	
neatly	 with	 reductive	 racial	 categories	 often	 employed	 to	 represent	
geographic	 origin.”39	 	 Consequently,	 making	 health	 decisions	 based	
upon	race	can	lead	to	more	mistakes	and	thus	worse	health	outcomes.40		
Nevertheless,	 there	 is	 sometimes	 a	 correlation	 between	 self-
identified	 racial	 groups	 and	 genetic	 characteristics,	 given	 that	 racial	
categories	 often	 are	 based	 on	 the	 geographic	 location	 of	 a	 person’s	





















	 40	 See	Scientists	Call	 for	the	Removal	of	Race	 in	Genetics	Research,	WHYY	(Feb.	18,	
2016),	https://whyy.org/segments/scientists-call-for-the-removal-of-race-in-genetics-
research/	(“[B]ecause	of	the	myth	that	sickle	cell	is	a	black	disease,	or	cystic	fibrosis	is	a	
white	 disease,	 white	 patients	 may	 be	 under	 diagnosed	 for	 sickle	 cell	 and	 other	




among	 individuals	 of	 different	 races	 or	 ethnicities.41	 	 A	 2015	 study	
concluded	that	about	20	percent	of	newly	approved	drugs	have	different	
responses	 based	 on	 the	 user’s	 race	 or	 ethnicity.42	 	 For	 example,	
individuals	of	African	or	Mediterranean	descent	more	commonly	have	a	




specific	 genetic	 differences.44	 	 For	 many	 race-specific	 disposition	
differences,	however,	a	specific	genetic	difference	is	not	known.45			
Aside	 from	 genetics,	 race	 is	 also	 relevant	 because	 of	 social	
determinants	 of	 health.46	 	 Differences	 in	 access	 to	 healthcare,	
employment,	 and	 clean,	 safe	 living	 conditions	 can	 lead	 to	 data	 that	
reflect	 racial	differences	 in	health	outcomes.47	 	These	disparities	 “are	
engineered	 from	 a	 great	 number	 of	 social	 inequalities	 that	
disproportionately	 impact	 certain	 groups.”48	 	 Negative	 healthcare	
outcomes	are	not	a	result	of	racial	differences—rather,	the	healthcare	
disparities	 themselves	 are	 forms	 of	 “racial	 inequities	 driven	 by	
injustice.”49	 	With	 so	many	 social	 factors	 at	 play,	 conclusions	 cannot	
always	be	accurately	drawn	about	racial	or	genetic	predispositions	to	
health	 outcomes.50	 	 In	 a	 perfect	world,	 doctors	would	 consider	 their	
patients’	social	conditions	rather	than	race,	especially	when	caring	for	
minority	populations.51	
Some	scholars	argue	 that	 “racial	 categories	are	weak	proxies	 for	


















gue/	 (“[M]odern	genetics	 research	 is	 operating	 in	 a	 paradox,	 which	 is	 that	 race	 is		
understood	to	be	a	useful	tool	to	elucidate	human	genetic	diversity,	but	on	the	other	




emergency	 physician,	 disagrees,	 arguing,	 “[r]ather	 than	 a	
risk	factor	that	 predicts	 disease	 or	 disability	 because	 of	 genetic	
susceptibility,	 race	 is	 better	 conceptualized	 as	 a	 risk	marker—of	
vulnerability,	bias	or	systemic	disadvantage.”53		She	argues	that	because	
of	 the	 ubiquity	 of	 racial	 disparities	 in	 healthcare,	 we	 should	 not	 be	






Social	 determinants	 affect	 responses	 to	 drugs	 or	 vaccines	 and	
should	 be	 considered	 during	 the	 clinical	 trial	 process	 by	 enrolling	
diverse	 trial	 participants.	 	Differences	 in	people’s	 underlying	medical	
conditions,	 for	 example,	 can	 affect	 vaccine	 effectiveness.56	 	 In	
individuals	 with	 preexisting	 conditions	 such	 as	 diabetes	 or	 HIV	
infection,	 both	 of	which	 affect	 Black	Americans	 at	 a	 higher	 rate	 than	
White	 Americans,	 vaccines	 have	 proven	 to	 be	 less	 effective.57		
Behavioral	 factors,	 such	 as	 smoking,	 alcohol	 consumption,	 exercise,	
sleep,	 and	 psychological	 stress,	 and	 nutritional	 factors,	 such	 as	 body	
mass	 index	 and	 nutritional	 status,	 also	 contribute	 to	 variations	 in	
vaccine	 responses—both	 the	 protection’s	 efficacy	 and	 duration.58		
Because	 vaccine	 effectiveness	 can	 be	 impacted	 by	 differences	 in	
underlying	conditions	and	can	vary	in	groups	of	people	not	included	or	
well-represented	 in	clinical	 trials,	vaccines	 that	 the	FDA	approves	 for	









	 56	 Ensuring	COVID-19	Vaccines	Work,	CTRS.	FOR	DISEASE	CONTROL	&	PREVENTION	 (Dec.	
13,	2020),	https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness.html.	
	 57	 Ananya	 Mandal,	 Vaccine	 Effectiveness,	 NEWS	 MED.	 (June	 5,	 2019),	 https://
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	 58	 For	 example,	 both	 adults	 and	 children	who	 are	 infected	with	HIV	 show	 lower	
responses	to	various	vaccines,	including	tetanus	and	measles,	and	patients	with	diabetes	
mellitus	 are	 associated	 with	 lower	 responses	 to	 Hepatitis	 B	 vaccination.	 	 Petra	
Zimmermann	&	Nigel	Curtis,	Factors	That	Influence	the	Immune	Response	to	Vaccination,	









new,	 the	 COVID-19	 pandemic	 highlights	 how	 much	 more	 work	 still	
needs	 to	 be	 done.	 	 Because	 COVID-19	 disproportionately	 affects	








living	 and	 working	 conditions,	 reinforce	 these	 disparities,	 placing	
minority	 communities	 at	 a	 disadvantage	 during	 the	 COVID-19	
pandemic.60	 	 The	 disproportionate	 impact	 that	 the	 pandemic	 has	 on	
racial	and	ethnic	minority	groups	highlights	relevant	issues	in	medical,	
social,	 economic,	 and	 political	 contexts	 that	 have	 existed	 since	 long	
before	the	pandemic.61	
Minority	 groups	 that	 are	 disproportionately	 affected	 by	 chronic	
medical	conditions	and	lower	access	to	health	care	have	worse	COVID-
19	 infection	 and	 mortality	 rates.62	 	 In	 cities	 like	 New	 York	 and	 San	
Francisco,	Black	and	Hispanic	Americans	face	higher	rates	of	mortality,	
infection,	and	death	from	COVID-19.63		Compared	to	White	Americans,	
Black	 Americans	 are	 disproportionately	 burdened	 by	 chronic	
preexisting	 conditions	 such	 as	 diabetes	 mellitus,	 hypertension,	 and	
obesity,	 all	 of	 which	 increase	 a	 patient’s	 risk	 of	 severe	 COVID-19	
infection	and	mortality;	this	longstanding	disparity	directly	contributes	
 
	 60	 CDC	 data	 shows	 that	 20.1	 percent	 of	 COVID-19	 cases	 were	 Black	 Americans,	
though	 they	make	up	only	13.4	percent	of	 the	population.	 	Similarly,	33.5	percent	of	












to	 disproportionately	 high	 infection	 rates	 and	 negative	 outcomes	 for	
Black	 Americans	 with	 COVID-19.64	 	 Chronic	 preexisting	 medical	
conditions	are	further	exacerbated	by	less	access	to	quality	healthcare.65		
Black	 Americans,	 Hispanic	 Americans,	 and	 Native	 Americans	 have	
higher	uninsured	rates	compared	to	White	Americans	(12	percent,	19	
percent,	 and	 22	 percent,	 respectively,	 compared	 to	 8	 percent),	 in	
addition	to	living	in	areas	with	lower	quality	medical	care.66		If	infected	




for	 Whites,	 the	 pre-COVID-19	 poverty	 rates	 for	 Black	 Americans,	
Hispanic	Americans,	and	Native	Americans	were	22	percent,	19	percent,	
and	 24	 percent,	 respectively.67	 	 Lower-income	 individuals	 lack	 the	
financial	 security	 to	make	 necessary	 “healthful	 decisions”	 during	 the	
pandemic.68	 	 In	 New	 York	 City,	 75	 percent	 of	 frontline	 “essential”	
workers	are	people	of	color	who	were	unable	to	work	from	home,	many	
of	 whom	 even	 continued	 to	 use	 public	 transportation	 as	 their	 only	
means	of	getting	to	work.69		Minority	communities	also	frequently	have	
higher	 housing	 density	 and	 are	 more	 likely	 to	 live	 with	 multiple	
generations	 of	 family	 members,	 circumstances	 that	 make	 social	
distancing	 much	 more	 difficult,	 if	 not	 impossible.70	 	 Other	 social	
determinants,	such	as	 language	barriers	and	health	 illiteracy,	prevent	
essential	 health	 information	 about	 the	 pandemic	 from	 being	
communicated	to	some	minority	populations.71		As	a	result,	the	risk	of	
COVID-19	 spreading	 through	 these	 communities	 is	 higher	 than	other	


















Researchers	 and	 drug	 developers	 have	 historically	 failed	 at	
achieving	inclusiveness	in	clinical	trials,	and	the	clinical	trials	for	COVID-
19	 treatments	 and	 the	 development	 of	 a	 COVID-19	 vaccine	 are	 no	
different.73	 	 So	 far,	 COVID-19	 treatment	 trials	 have	 not	 included	
sufficiently	diverse	populations,	despite	the	fact	that	Black	and	Latinx	
communities	have	been	disproportionately	affected	by	the	disease.74		A	
study	 conducted	 by	 researchers	 at	 the	 University	 of	 California	 San	
Francisco	 assessed	 the	 race	 representation	 in	 COVID-19	 treatment	
studies	 through	 July	 10,	 2020.75	 	 The	 results	 found	 that	 race	 and	
ethnicity	 were	 inconsistently	 collected	 and	 reported	 and	 that	 “Black	
patients	were	 consistently	underrepresented	 relative	 to	 their	disease	




same	 study,	 Hispanic	 patients	 were	 vastly	 overrepresented—51	
percent	 of	 the	 study	 population,	 but	 32.7	 percent	 of	 all	 cases—and	




Knowing	 the	 history	 of	 clinical	 research	 with	 minority	
communities,	scientists	realize	their	obligation	to	create	a	vaccine	that	
works	for	the	diverse	populations	who	will	need	it.		One	of	the	leading	
scientists	 on	 the	 Pfizer	 vaccine	 study	 understands	 the	 importance	 of	
diversity	 in	 understanding	 how	 a	 drug	 or	 vaccine	 will	 work	 in	 the	
general	population:	
A	question	we	always	ask	ourselves,	when	we	do	clinical	trials,	
are	 how	 generalizable	 will	 results	 be	 to	 people	 who	 suffer	
from	 the	disease?	 .	.	.	 If	 you	did	a	 study	 in	a	majority-White	
population	with	very	little	Black	individuals,	when	we	do	get	

















or	 Native	 American	 participants,	 leading	 the	 company	 to	 slow	 trial	
enrollment	to	prioritize	minority	recruitment.82		Investigators	working	
on	 the	 clinical	 trial	 reported	 that	while	minority	 recruitment	 lagged,	
trial	 quotas	 were	 quickly	 filled	 by	 “overwhelming	 interest	 in	
participation	from	[W]hite	volunteers.”83		And	in	an	online	registry	used	














Lag	 on	 Participant	 Diversity,	 WASH.	 POST	 (Aug.	 27,	 2020),	 https://www.washing-
tonpost.com/health/2020/08/27/large-us-covid-19-vaccine-trials-are-halfway-en-
rolled-lag-participant-diversity/.	




	 82	 Justine	 Coleman,	 Moderna	 Vaccine	 Trials	 Slowed	 by	 Insufficient	 Minority	

















in	 clinical	 research,	 especially	 trials	 related	 to	 COVID-19,	 to	 address	
disparities	 in	 health	 outcomes.88	 	 The	 COVID-19	 pandemic	 has	 given	
medical	and	healthcare	professionals	a	more	powerful	voice	in	society.		
These	 professionals	 now	 have	 the	 opportunity	 to	 unravel	 the	 old	
system,	filled	with	social	inequities,	to	design	a	“more	equitable	system	
that	 promotes	 health	 for	 all	 Americans	 irrespective	 of	 social	 or	
economic	background.”89	
III.		THE	ROLE	OF	THE	FDA	IN	REGULATING	CLINICAL	TRIALS	
The	FDA	 is	 the	 federal	 agency	 responsible	 for	 regulating	 clinical	
trials.		The	FDA	derives	much	of	its	statutory	authority	from	the	Food,	
Drug,	and	Cosmetics	Act,	which	states	that	missions	of	the	FDA	include	




consumers,	 users,	 [and]	 manufacturers	 .	.	.	 of	 regulated	 products.”91		
Further,	 the	 FDA’s	 programs	 and	 policies	 should	 encourage	
collaboration	with	“the	National	Institutes	of	Health,	and	other	science-
based	Federal	agencies,	to	enhance	the	scientific	and	technical	expertise	
available	 .	.	.	 with	 respect	 to	 the	 development,	 clinical	 investigation,	
[and]	 evaluation	 .	.	.	 of	 emerging	 medical	 therapies.”92	 	 The	 FDA	 has	
promulgated	 numerous	 regulations	 to	 execute	 its	 statutory	missions	
relating	 to	 clinical	 trials.93	 	 For	 example,	 one	way	 the	 FDA	 regulates	
clinical	trials	is	by	requiring	sponsors	to	submit	an	Investigational	New	
Drug	Application	(IND)	to	the	FDA	before	conducting	a	clinical	trial.94	
New,	 untested	 drugs	 typically	 go	 through	 three	 phases	 of	
investigation,	referred	to	as	Phases	I,	II,	and	III.95		Phase	I	investigations	
are	 closely	 monitored,	 as	 they	 primarily	 focus	 on	 determining	 the	
maximum	 dose	 of	 a	 drug	 that	 can	 be	 administered	 safely	 without	















short-term	 side	 effects	 associated	 with	 the	 drug.97	 	 Phase	 III	





The	 FDA	 has	 the	 power	 to	 place	 a	 clinical	 hold	 to	 suspend	 an	
ongoing	investigation,100	and	utilizes	this	power	to	enforce	compliance	
with	 regulations	 related	 to	 clinical	 trials.	 	 In	 existing	 regulations,	 the	
FDA	lists	a	number	of	specified	grounds	for	issuing	a	clinical	hold	at	each	
phase	of	the	trial	process.101		For	example,	the	FDA	may	place	Phase	II	
or	 III	 studies	 on	 hold	 if	 the	 “plan	 or	 protocol	 for	 the	 investigation	 is	
clearly	deficient	in	design	to	meet	its	stated	objectives.”102	 	 If	the	FDA	
identifies	a	study	deficiency,	it	will	“attempt	to	discuss	and	satisfactorily	
resolve	 the	 matter	 with	 the	 sponsor	 before	 issuing	 the	 clinical	 hold	
order.”103	 	 If	a	hold	order	is	issued,	the	trial	may	not	resume	until	the	
FDA	 lifts	 the	 order	 because	 the	 sponsor	 has	 either	 (1)	 corrected	 the	




















	 105	 Who	We	 Are,	 NAT’L	 INSTS.	HEALTH,	 https://www.nih.gov/about-nih/who-we-are	
(last	visited	Oct.	24,	2021).	








a	permissible	consideration	 in	determining	whether	such	 inclusion	 is	
inappropriate.”108		The	Act	also	provides	exceptions	to	the	requirement	
for	 inclusion	of	minorities	 in	 clinical	 trials	when	 “there	 is	 substantial	





in	 all	 NIH-funded	 clinical	 research,	 unless	 a	 clear	 and	
compelling	 rationale	 and	 justification	 establishes	 to	 the	
satisfaction	 of	 the	 relevant	 Institute/Center	 Director	 that	
inclusion	 is	 inappropriate	with	 respect	 to	 the	 health	 of	 the	
subjects	or	the	purpose	of	the	research	.	.	.	.		The	inclusion	of	
.	.	.	 members	 of	 minority	 groups	 and	 their	 subpopulations	
must	be	addressed	in	developing	a	research	design	or	contract	




other	 sources.”111	 	 Policy	 exceptions	 may	 be	 permitted	 based	 on	
“compelling	 rationale	 and	 justification”	 at	 the	 NIH	 Director’s	
discretion.112	 	 Evidence	 showing	 whether	 or	 not	 “race/ethnicity	
differences	 in	 the	 intervention	 effect	 are	 to	 be	 expected”	 must	 be	
reviewed	during	the	proposal	of	an	NIH-defined	Phase	III	clinical	trial.113		
 
	 107	 Nat’l	 Insts.	 Health,	 NIH	 Policy	 and	 Guidelines	 on	 the	 Inclusion	 of	 Women	 and	
Minorities	 as	 Subjects	 in	 Clinical	 Research,	 NIH	 GRANTS	 &	 FUNDING	 (Dec.	 6,	 2017),	
https://grants.nih.gov/policy/inclusion/women-and-minorities/guidelines.htm.	 	 An	
amendment	to	the	policy	was	made	on	November	28,	2017.		The	only	significant	change	
to	 the	 policy	 is	 the	 requirement	 that	 sex/gender,	 race,	 and/or	 ethnicity	 analysis	 are	


















race	 and	 ethnicity	data.115	 	Many	of	 these	 initiatives	have	 focused	on	
broadening	 eligibility	 criteria,	 including	 “characteristics	 such	 as	 age,	




In	 2014,	 the	 FDA	 released	 the	 “FDA	Action	 Plan	 to	 Enhance	 the	
Collection	 and	 Availability	 of	 Demographic	 Subgroup	 Data”	 (“Action	
Plan”).117		The	Action	Plan	was	published	in	response	to	Section	907	of	
the	Food	and	Drug	Administration	Safety	and	 Innovation	Act	of	2012	
(FDASIA),	 which	 directed	 the	 FDA	 to	 provide	 Congress	 information	
regarding	demographic	subgroup	participation	in	clinical	trials	and	the	
availability	of	safety	and	efficacy	data	for	specific	subgroups.118		Section	
907	 also	 mandated	 the	 FDA	 to	 issue	 an	 action	 plan	 making	
recommendations	to	improve,	
the	 completeness	 and	 quality	 of	 analyses	 of	 data	 on	
demographic	subgroups	in	summaries	of	product	safety	and	
effectiveness	 data	 and	 in	 labeling;	 .	.	.	 the	 inclusion	 of	 such	
data,	 or	 the	 lack	 of	 availability	 of	 such	 data	 in	 labeling;	 .	.	.	
[and]	 the	public	 availability	 of	 such	data	 to	 patients,	 health	
care	providers,	and	researchers.119			
The	Action	Plan	acknowledged	 that	 certain	 subgroups,	 including	
Blacks,	Hispanics,	and	U.S.	Asians,	are	less	likely	to	participate	in	clinical	
trials	compared	to	the	population	as	a	whole,	and	further	acknowledged	




TRIALS:	 GUIDANCE	 FOR	 INDUSTRY	 AND	 FOOD	 AND	 DRUG	 ADMINISTRATION	 STAFF	 1	 (2016)	
[hereinafter	2016	GUIDANCE	DOCUMENT];	see	generally	Clinical	Trials	Guidance	Documents,	
















Plan	 noted	 several	 barriers	 to	 participating,	 including	 a	 shortage	 of	
investigators	who	have	access	to	patients	who	belong	to	demographic	
subgroups;	“patients	and	families	with	negative	attitudes	about	medical	
research	 and	 concerns	 about	 risk”;	 patient	 inconvenience,	 such	 as	
transportation	requirements	and	geographic	location;	and	insurance	or	
socioeconomic	status	affecting	access	 to	 trials	and	healthcare.122	 	The	
Action	 Plan	 stated	 that	 the	 “FDA	 fully	 supports	 efforts	 to	 encourage	







to	 better	 understand	 contemporary	 barriers	 to	 participation.124	 	 The	
Action	 Plan	 also	 proposed	 increasing	 effective	 communication	 with	
demographic	 subgroups	 about	 clinical	 trial	 participation,	 including	
distributing	 information	 in	 both	 English	 and	 Spanish,	 as	 well	 as	








In	 2015,	 the	 FDA’s	 Center	 for	 Drug	 Evaluation	 and	 Research	
(CDER)	 began	publishing	Drug	Trials	 Snapshots	 to	make	 available	 to	














sex,	 age,	 or	 race,	 and	 provides	 a	 breakdown	 of	 the	 percentages	 of	
participants	based	on	sex,	age,	and	race.128		At	the	end	of	each	year,	the	
FDA	 releases	 the	 “Drug	 Trials	 Snapshots	 Summary	 Report,”	 which	
further	breaks	down	demographic	subgroups	of	all	participants	in	trials	
for	approved	drugs.129		In	the	annual	report,	demographic	subgroups	are	
broken	 down	 into	 White,	 Black	 or	 African	 American,	 Asian,	 and	
Hispanic.130	 	 For	 some	drugs,	 certain	demographic	 information	 is	not	
reported.131	
The	Snapshots’	purpose	is	to	enhance	transparency	and	“promote	
dialogue	 on	 the	 appropriate	 representation	 of	 different	 subgroups	 in	
clinical	trials.”132		While	a	thoughtful	initiative,	the	Snapshots	have	two	




thirty	 days	 of	 drug	 approval	 and	 are	 not	 updated	 to	 reflect	 new	
information	as	 it	may	become	available.133	 	Because	the	FDA	typically	










issued	 a	 guidance	 document	 in	 2016	 to	 establish	 a	 “standardized	
 
	 127	 Drug	 Trials	 Snapshots,	 U.S.	 FOOD	 &	 DRUG	 ADMIN.	 (Apr.	 9,	 2021)	 [hereinafter		
Snapshots],	 https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-
snapshots.		













approach	 for	 collecting	 and	 reporting	 race	 and	 ethnicity	 data	 in	
submissions	for	clinical	trials,”	because	the	use	of	standardized	methods	
and	 terminology	 ensures	 that	 data	 is	 collected	 uniformly	 and	
consistently.137	 	 Per	 FDA	 regulations,	 trial	 sponsors	 are	 expected	 to	
“enroll	participants	who	reflect	the	characteristics	of	clinically	relevant	
populations	 with	 regard	 to	 age,	 sex,	 race,	 and	 ethnicity.”138	 	 The	
guidance	document	provides	that,		
A	 plan	 to	 address	 inclusion	 of	 clinically	 relevant	
subpopulations	should	be	submitted	.	.	.	to	the	Agency	at	the	
earliest	phase	of	development	and,	for	drugs	and	biologics,	no	
later	 than	 the	 end	 of	 the	 phase	 2	 meeting.	 	 Inadequate	
participation	 and/or	 data	 analyses	 from	 clinically	 relevant	
subpopulations	can	lead	to	insufficient	information	pertaining	
to	 medical	 product	 safety	 and	 effectiveness	 for	 product	
labeling.139	





Reauthorization	 Act	 of	 2017	 (FDARA),	 which	 required	 the	 FDA	 to	
“convene	 a	 public	 meeting	 to	 discuss	 clinical	 trial	 inclusion	 and	
exclusion	 criteria	 to	 inform	 the	 guidance”	 and	 issue	 a	 report	 on	 the	
matter.141		This	guidance	document	focuses	primarily	on	how	sponsors	
can		increase	underrepresented	populations’	enrollment	in	clinical	trials	
using	 inclusive	 trial	 practices.142	 	 It	 also	 discusses	 “improving	 trial	
recruitment	so	that	the	participants	enrolled	in	trials	will	better	reflect	
the	population	most	likely	to	use	the	drug.”143		
Obstacles	 to	 enrolling	 in	 clinical	 trials	 include	 the	 burden	 of	
frequent	visits	to	specific	sites,	financial	costs	from	traveling	or	missing	
work,	 and	 distrust	 of	 clinical	 research	 among	 certain	 populations.144		
The	 FDA	 suggests	 sponsors	 can	 improve	 the	 diversity	 of	 study	
 
	 137	 2016	GUIDANCE	DOCUMENT,	supra	note	115	at	1.		
	 138	 2020	GUIDANCE	DOCUMENT,	 supra	 note	 116,	 at	 5;	 see	 21	 C.F.R.	 §§	 314.50(d)(v),	
(vi)(a)	(Safety	and	efficacy	data	in	NDAs	“must	be	presented	by	.	.	.	racial	subgroups	and	












clinical	 trial	 and	 provides	 a	 number	 of	 potential	 approaches.145	 	 For	
example,	the	section	titled	“Make	Trial	Participation	Less	Burdensome	
for	 Participants”	 suggests	 that	 trial	 sponsors	 should	 take	 note	 of	
recruitment	 challenges	 that	 the	 study’s	 planned	 visit	 schedule	 may	
cause	and	consider	reducing	the	number	of	visits,	increasing	flexibility	
in	visit	windows	when	possible,	using	technology	to	replace	in-person	
visits,	 or	 providing	 financial	 reimbursements	 for	 travel	 or	 lodging	
expenses.146	 	Another	 section	 titled	 “Adopt	Enrollment	and	Retention	
Practices	That	Enhance	Inclusiveness”	urges	trial	sponsors	to	work	with	
communities	to	better	understand	why	participants	may	be	reluctant	to	
enroll	 in	 a	 clinical	 trial	 to	 better	 address	 participants’	 needs	 and	 to	
involve	the	participants,	their	families,	and	patient	advocates	in	the	trial	
design	 process;	 to	 select	 trial	 sites	 located	 in	 areas	 with	 higher	




It	 is	worth	 noting	 that	while	 guidance	 documents	 represent	 the	
“current	thinking”	on	a	topic,	the	guidance	is	“not	binding	on	the	FDA	or	
the	 public”	 and	 creates	 no	 legally	 enforceable	 responsibilities.148		












not	 establish	 legally	 enforceable	 responsibilities.	 	 Instead,	 guidances	 describe	 the	
Agency’s	current	thinking	on	a	topic	and	should	be	viewed	only	as	recommendations,	




Overcoming	 Critical	 Barriers,	 44	 CURRENT	 PROBLEMS	 IN	 CARDIOLOGY	 148,	 150	 (2019)	
(“[D]espite	major	efforts,	including	those	from	the	US	FDA	and	the	Revitalization	Act	of	





For	 example,	 the	 Center	 for	 Information	 and	 Study	 on	 Clinical	
Research	 Participation	 (CISCRP)	 is	 “dedicated	 to	 educating	 and	
informing	 the	 public,	 patients,	 medical/research	 communities,	 the	
media,	and	policy	makers	about	clinical	research	and	the	role	each	party	
plays	 in	 the	 process.”150	 	 CISCRP	 offers	 a	 number	 of	 services	 and	
programs	to	help	consumers	find	trials	that	are	relevant	to	their	specific	
needs	and	learn	more	about	clinical	trials	by	providing	“plain	language	
translation”	 of	 research	 documents.151	 	 CISCRP	 also	 focuses	 on	
community	 engagement	 by	 increasing	 awareness	 about	 clinical	 trials	
through	media	 campaigns	 and	 hosting	 educational	 events	 in	 diverse	
communities	to	further	enable	individuals	to	make	informed	decisions	








undertaking	 various	 initiatives	 to	 increase	 diversity	 in	 their	 clinical	
trials	 by	 providing	 “diversity	 and	 cultural	 sensitivity	 training”	 for	 its	
clinical	 trial	 sites;	 focusing	 on	 opening	 its	 trials	 at	 sites	 that	 serve	 a	




design	 which	 reflect	 the	 patient	 population	 affected	 by	 a	 specific	
disease;	and	collaborating	on	a	study	with	the	Tufts	Center	for	the	Study	
of	 Drug	 Development	 (Tufts	 CSDD)	 to	 learn	 more	 from	 patients,	
healthcare	 experts,	 and	 community	 members	 about	 the	 obstacles	
patients	 face	 in	 clinical	 trial	 participation.154	 	 These	 initiatives	 reflect	
















is	 “critical	 to	 public	 health	 and	 well-being	 through	 increased	
representation	of	 the	populations	who	experience	a	condition.”156	 	To	
increase	minority	patient	recruitment,	Pfizer	is	employing	community	
outreach	 programs	 in	 churches,	 schools,	 town	 halls,	 and	 other	
community	 centers	 to	 raise	 awareness	 and	 increase	 education	 about	
clinical	trials.157		Realizing	the	importance	of	investigator	training,	Pfizer	
also	 developed	 a	 recruitment	 tracking	 system	 to	 “help	 establish	
diversity	as	a	key	scientific	variable	across	[its]	research	portfolio.”158	
While	these	initiatives	represent	a	good	start,	 to	most	effectively	
increase	 diversity	 in	 clinical	 trials,	 the	 medical	 community	 must	 be	




often	 have	 racial	 preferences	 in	 healthcare,	 and	 providers	 should	
strongly	consider	these	preferences	to	optimize	care	quality.160		Studies	















	 160	 Kimani	 Paul-Emile,	 Patients’	 Racial	 Preferences	 and	 the	 Medical	 Culture	 of	
Accommodation,	 60	UCLA	L.	REV.	 462,	 486–87	 (2012)	 (“A	 patient	must	 be	willing	 to	
speak	 candidly	 about	 personal	 and	 potentially	 uncomfortable	 or	 embarrassing	
information;	to	submit	to	bodily	examination,	including	attention	to	all	manner	of	injury	
and	 abuse;	 to	 confide	in	and	 communicate	 openly	with	 the	 physician;	 to	 rely	 on	 the	











should	 issue	 a	 rule	 mandating	 increased	 diversity	 in	 clinical	 trial	
participants	when	feasible	and	clinically	appropriate	as	a	condition	of	
obtaining	marketing	authorization.	
Many	 have	 criticized	 the	 FDA’s	 attempts	 to	 address	 diversity	 in	
clinical	 trials	 and	have	urged	 for	more	 compelling	action.	 	 In	a	white	
paper	 report	about	 increasing	minority	participation	 in	clinical	 trials,	
the	Endocrine	Society	asserted	that	the	FDA	should	require	rather	than	
recommend	adherence	to	its	guidelines.164		During	the	public	comment	









should	 provide	 direction	 specific	 to	 involving	 African	 Americans,	
Latin[x]	and	Asians.”168	








its	 policy	 to	 require	 appropriate	 inclusion	 of	 underrepresented	
populations	 in	 all	 clinical	 trials;	 [i]mplement	 penalties	 for	 non-
compliance	with	inclusion	policies	in	clinical	trials;	[and]	[i]mplement	
















the	 FDA	 “‘does	 not	 have	 the	 regulatory	 authority	 to	 require	 specific	
levels	of	minority	representation	in	clinical	trials’”—which,	while	true—
does	 not	 prevent	 the	 FDA	 from	 demanding	 more	 generalized	
requirements.172			
For	 these	reasons,	 the	FDA	should	promulgate	an	administrative	
rule	 that	will	 place	 a	 legally	 enforceable	 duty	 on	 drug	 developers	 to	







differences	 in	 safety	 or	 efficacy.	 	 In	 addition	 to	 demographic-based	
safety	and	efficacy	information,	the	IND	must	identify	the	demographics	
of	 the	 trial	 participants	 compared	 to	 the	 demographics	 of	 those	
generally	affected	by	the	disease.		If	there	is	a	significant	lack	of	diversity	









Proportionate	 diversity	 levels	 need	 not	 be	 reached	 if	 enrolling	
diverse	 participants	 proves	 too	 difficult	 despite	 best	 efforts,	 or	 if	
participants	 opt	 not	 to	 enroll	 in	 trials	 despite	 recruitment	 efforts.		
Sponsors,	however,	will	bear	 the	burden	of	proving	 that	 they	made	a	
“good	 faith	 effort”	 to	 recruit	 diverse	 trial	 participants.	 	 To	 do	 so,	
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“good	 faith	effort”	may	also	be	 supported	by	an	 increased	number	of	
principal	 investigators	 from	 minority	 communities	 or	 proof	 that	
minority	patients	were	counseled	or	signed	consent	to	participate	in	a	







goal	was	 to	manufacture	 and	deliver	300	million	doses	 of	 a	 safe	 and	
effective	 vaccine	 by	 January	 2021.176	 	 Though	 adding	 a	 diversity	
requirement	may	 initially	 slow	 a	 study’s	 progress	 due	 to	minorities’	
distrust	 of	 the	medical	 community,177	 there	will	 be	 no	 “shortages”	 of	
potentially	 eligible	 patients	 that	 would	 dramatically	 slow	 drug	
development.	 	After	all,	 instances	of	COVID-19	and	other	diseases	are	
much	higher	in	minority	communities.		Even	so,	as	a	safeguard,	lack	of	




health	 disparities	 and	 generally	 improving	 health	 outcomes	 for	
minority	 communities.	 	 We	 cannot	 undermine	 the	 importance	 of	
knowing	that	the	government	is	looking	out	for	minority	communities’	
best	 interests	 and	 no	 longer	 standing	 passively	 by.	 	 By	 failing	 to	
introduce	 any	 binding	 regulations,	 government	 agencies	 have	 sent	 a	
clear	message	that	the	battle	for	equality	is	not	one	they	will	help	fight.		




19	 pandemic,	 which	 continues	 to	 disproportionately	 affect	 minority	
communities,	 including	 Black	 Americans,	 Latinx,	 and	 Natives	
Americans.		Despite	this	fact,	COVID-19	treatment	and	vaccine	trials	did	
 







the	 fact	 that	 clinical	 trials	 generally	 lack	 diversity	 compared	 to	 the	
population	 as	 a	 whole,	 with	 minorities	 being	 consistently	
underrepresented.		As	a	result,	safety	and	efficacy	data	frequently	do	not	
reflect	 racial	 and	 ethnic	 differences	 and	 may	 not	 provide	 useful	
information	for	many	people	using	a	drug	or	 intervention.	 	COVID-19	
treatment	and	vaccine	trials	that	do	not	include	minority	participants	
may	 not	 be	 safe	 or	 effective	 in	 these	 populations.	 	 Understandably,	
minority	patients	may	not	 feel	safe	pursuing	treatment	or	receiving	a	
vaccination	 that	 has	 not	 been	 proven	 safe	 or	 effective	 in	 their	
demographic	class.	
To	 reduce	 these	 health	 disparities,	 diversity	 of	 clinical	 trial	
participants	must	increase.		While	government	agencies,	including	the	
NIH	and	the	FDA,	have	taken	some	steps	towards	increasing	inclusion	
in	 clinical	 trials,	 the	 FDA	 is	 in	 the	 best	 position	 to	 enforce	 change	
because	 the	 FDA	 ultimately	 controls	 which	 drugs	 and	 vaccines	 are	
approved	for	commercial	use.		So	far,	the	FDA	has	primarily	issued	non-
binding	 guidance	 documents	 that	 encourage	 drug	 developers	 to	
increase	diversity	 in	their	 trials.	 	These	documents	suggest	steps	that	
drug	developers	 can	 take	 to	 increase	diversity	during	 the	participant	





developers	 to	 increase	 diversity	 in	 their	 clinical	 trials	 before	 they	
approve	 drugs	 for	 general	 use.	 	 This	 rule	 would	 place	 a	 procedural	
requirement	on	the	drug	approval	process	and	put	the	burden	on	drug	
developers	to	prove	that	they	have	made	a	“good	faith	effort”	to	recruit	
diverse	trial	participants.		This	rule	would	be	similar	to	the	NIH	policy	
that	requires	minority	populations	to	be	included	in	NIH-funded	clinical	
research	unless	no	significant	distinguishable	racial	or	ethnic	safety	or	
efficacy	concerns	exist.		Increasing	inclusion	of	minority	populations	is	
an	 important	step	 towards	reducing	health	disparities	and	rebuilding	
trust	between	minority	populations	and	the	medical	community—goals	
with	critical	importance	which	cannot	be	ignored	during	the	COVID-19	
pandemic	and	moving	forward.		
	
	
